Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma
Open Access
- 9 June 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1171811
Abstract
Background: Patients with pancreatic duct adenocarcinoma (PDAC) have varied prognoses that depend on numerous variables. However, additional research is required to uncover the latent impact of ubiquitination-related genes (URGs) on determining PDAC patients’ prognoses.Methods: The URGs clusters were discovered via consensus clustering, and the prognostic differentially expressed genes (DEGs) across clusters were utilized to develop a signature using a least absolute shrinkage and selection operator (LASSO) regression analysis of data from TCGA-PAAD. Verification analyses were conducted across TCGA-PAAD, GSE57495 and ICGC-PACA-AU to show the robustness of the signature. RT-qPCR was used to verify the expression of risk genes. Lastly, we formulated a nomogram to improve the clinical efficacy of our predictive tool.Results: The URGs signature, comprised of three genes, was developed and was shown to be highly correlated with the prognoses of PAAD patients. The nomogram was established by combining the URGs signature with clinicopathological characteristics. We discovered that the URGs signature was remarkably superior than other individual predictors (age, grade, T stage, et al). Also, the immune microenvironment analysis indicated that ESTIMATEscore, ImmuneScores, and StromalScores were elevated in the low-risk group. The immune cells that infiltrated the tissues were different between the two groups, as did the expression of immune-related genes.Conclusion: The URGs signature could act as the biomarker of prognosis and selecting appropriate therapeutic drugs for PDAC patients.Keywords
This publication has 34 references indexed in Scilit:
- A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic CancerFrontiers in Oncology, 2020
- S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancerThe FASEB Journal, 2020
- Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic CancerCancers, 2020
- The Ancient Chinese Decoction Yu-Ping-Feng Suppresses Orthotopic Lewis Lung Cancer Tumor Growth Through Increasing M1 Macrophage Polarization and CD4+ T Cell CytotoxicityFrontiers in Pharmacology, 2019
- Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic CancerFrontiers in Oncology, 2019
- Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras statusClinical Epigenetics, 2019
- Expression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinomaScientific Reports, 2018
- Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinomaPancreatology, 2018
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studiesCancer Medicine, 2017
- Progress report. Cancer of the pancreas.Gut, 1977